Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You’re right Nice big bid, welcome to the club buddy hope you get your shares ...
Board cleaned, Glad to see clean up... outdated info., I Had contacted Jim homes a month ago telling them that Investor Hub information was outdated...Wonder if anybody else contacted them...appears they Literally listened !!! Getting closer to launch
Cyrcadia Data Services (Cds) Limited:
Summary
Cyrcadia Data Services (Cds) Limited was set up on Thursday the 20th of April 2017. Their current partial address is County Wicklow, and the company status is Normal. The company's current directors have been the director of 32 other Irish companies between them; 4 of which are now closed.
Company Vitals
* Company Name:?Cyrcadia Data Services (Cds) Limited
* Time in Business:?1 Year
* Company Number:?602697
* Current Status:?NORMAL?
* Principal Activity:?[6311] Data Processing, Hosting and Related Activities
* May Trade As:?Cyrcadia Data Services Cds Ltd
* ADD MY COMPANY DETAILS
*
* Registered Address:?No. 1 Main Street,?Blessington,?County Wicklow
* CDS Cyrcadia Data Services Limited Co# 602697 Registered 4/20/2017 (CRO Gazette 2017 pg4/7)
{Cyrcadia, Inc. Prepares for iTBra™ Product Launch and Expands Strategic Operations to Asia
Apr 25, 2017 Cyrcadia Data Services, Ltd.is a joint venture between Cyrcadia, Inc. and Cyrcadia Asia, Ltd., as an Ireland-based corporation...
Anonymised data is communicated directly to the Cyrcadia's core lab for analysis via your mobile device...Under the License and Collaboration Agreement, CI and CA have also established a joint venture, Cyrcadia Data Services, Ltd. to fund and develop the Cyrcadia health predictive analytics core lab. This entity will ensure improved accuracy in the technology as the companies feed in “large volumes” of data from their respective regions.}
April 20 New Co Registration:
https://www.cro.ie/DesktopModules/EasyDNNNews/DocumentDownload.ashx?portalid=0&moduleid=1179&articleid=1089&documentid=11370
https://www.benzinga.com/pressreleases/17/04/p9339511/cyrcadia-inc-prepares-for-itbra-product-launch-and-expands-strategic-op
I’m sure he’s here getting a sniff, every penny trader can’t refuse, it’s in the blood...New technology, mkt need is what’s driving this now since his past incredible DD 3 yrs ago (this guy put some serious time in). I agree though .05 no problem after launch & hopefully the Cyrcadia Health website updated & relaunched has some bite in it...
Death I fear not, but time that’s a whole new equation !
He should be...And his hard dedicated hours of research —just the early years before technology is finally taking us to launch...
Yes the 5 wearables, hey check this out post#114495 old DD post, doesn’t post here any more at least not with the old name...go to 4search.com, type in iTBra & go to article #63 ,,talk about hrs of work this guy has me crushed unfortunately he/she won’t respond to me, erases my post ASAP I saved an original copy just in case it mysteriously disappears... can’t find it I anymore, you can try though ???
Absolutely, that Mex device a complete fraud in the sense they copied the tech., they have so far to go...I’ll probably be traveling the cosmos...iTBra is the big kid & he’s making his deveu soon.
Regardless good find that link slipped by me, but the 1st one takes you to Cyrcadia Health!!!
Also, I just contacted the writer in regards to the launch date & the fact that I believe it is the first cancer detection Wearable about to go to MARKET...
iFlytech originall News Letter announcement of Cyrcadia interest, just in case havn’ Seen...tic toc
https://pbs.twimg.com/media/DgQxRmMUwAANPPn.jpg
(You can sign up & follow iFlytech News Letter on Twitter, waiting for the announcement when their tech has
been unleashed with the iTBra) (Also, sign up for Cisco News that News IoT internet of everything, their all
it...)
Cyrcadia Asia CEO Rob Royea (Formally Cyrcadia Health CEO), a man who gets it done, not my words, but those who know him—Open LINK below Linkedin & scroll to “Recommendations”. Tic toc tic...
https://www.linkedin.com/in/robroyea/
Agree, 3% of O/S may not be a problem once Dist. starts, small vol moved this 370% on spilled beans several
years ago, I guess 30-50-70Mil shares + will get the trader adrenaline glands excited...tic toc
Nice post Mead, certainly one Dec I am counting the days down !
Exactly it’s a Game changer, utilizing most advanced technology not available just a few yrs back
(But I already posted this, in different words)
Launch announcement exerts:
Reno, NV , Feb. 28, 2018 (GLOBE NEWSWIRE) --
Lifeline Biotechnologies, Inc, (“The Company”) (OTC PINK: LLBO) Provides Information to the Public and Updates It’s Shareholders.
Jim Holmes, Lifeline’s Cyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs.”
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
by admin | Feb 21, 2018 | News |
“Our priority now is to finalize and implement our marketing plan enabling the ramp up of sales as soon as possible in 2018 upon product delivery.”
“On behalf of the Cyrcadia, Inc. team, we thank you for your support as we bring this life saving technology to market. We will make every effort to ensure timely and profitable delivery of CI’s technology to the “U.S. market”and rest of world outside of the territories covered by CA.”
Sincerely,
Matt Benardis
CEO
Cyrcadia, Inc
Rob Royea Cyrcadia Asia CEO: Jan 2019 launch interview
Oct 31 2018: (I believe part 2 is Jan launch discussion)
https://cyrcadia.asia/2018/10/31/hkibc-all-about-money-features-rob-royea-cyrcadia-asia/#more-676
Reno, NV May 29, 2018, Cyrcadia Health “B” Warrant Acceleration Option
by admin | May 29, 2018 | News
Based on 2018 Go-To-Market plans, investment infusion is paramount in keeping on track and maintaining our accelerated pace. Our stakeholders have been essential in supporting our march to bring the most advanced Breast Health product to market.
“Principals of these companies have been involved with Cyrcadia Health for a number of years and have a deep understanding of our value proposition to bring significant value to our Go-To-Market launch,” says Matt Benardis, CEO.
May 4, 2018, Reno, NV. Expanded Go-To-Market Team
by admin | May 4, 2018 | News
Cyrcadia, Inc. is pleased to announce the addition of Marly Heidkamp, Chief Operating Officer, R.N., MSEd to the executive team to focus on execution of the Go-to- Market plan. Jim Holmes, CFO, say, “We are pleased to have an operations executive join our team who possesses medical product management experience as well. We are confident her leadership will bring added perspective to a product targeted for the female population.” Matt Benardis, CEO, added “We have already seen results from her leadership of the recent kick-off meeting with the comprehensive Go-To- Market team and her engagement of each department regarding oversight, organization and accountability.”
The human element of IoE changing the way breast cancer is detected
TechNovember 03, 2015 08:47
By Vatsun Thirapatarapong
10,540 Viewed
exerts-
Cisco and Cyrcadia Health are involved in the development of an “ iTBra”...
, iTBra will provide thousands of women with early warnings of cancer formation, enabling doctors to implement treatment plans to save lives in time.
Cisco has been following Cyrcadia Health’s efforts closely as their work is a major example of how innovation, made possible by the Internet of Everything, can change and ultimately save lives...
Cisco is chronicling the story of the iTBra by funding a documentary scheduled for release later this year...
More important, is the story of how the connected health industry – poised to be a billion market by 2018 – could change everything we know about medicine.
iTBra is only one example of the Internet of Everything at work in the healthcare industry. In the next three to five years, the number of health-related connected devices will soar. The globally connected health market will grow at an annual growth rate of 33 percent by 2019.
China's AI leader iFLYTEK invests in breast cancer detection wearable Cyrcadia Asia
2018-07-16 09:00:
exerts-
The Pre-A funding enables Cyrcadia to complete product development and launch into Hong Kong and other Asian markets in late 2018...
Commenting on the deal, Tao Xiaodong iFlytech Med Dir.,said: "We are excited to play a leading role in the development and launch of Cyrcadia's technology. iFlytek is already harnessing the power of AI in healthcare, but Cyrcadia's technology,...
As Cyrcadia's user base grows, it has the potential to be the world's largest data base of breast health and breast cancer incidence...
Asia Co-Investors Club
(Past Events)
exert-
Rob Royea, CEO of Cyrcadia Asia, shared his journey with us on 8th October, from the initial idea to the launch of a path-breaking device that has the potential to save millions of lives.
September 21, 2018
Ameing for Asia
exert-
High Demand for Breast Cancer Diagnosis and Treatment Products in Asia
iTBra, through its Hong Kong subsidiary. The company plans a further expansion into China, Indonesia, Malaysia, the Philippines, Singapore and Thailand before the end of the year...
Swiss Association & Swiss Chamber of Commerce
Joint Monthly Luncheon,
Oct8 2018
"Detected"
Guest Speaker: Rob Royea CEO, Cyrcadia Asia, Ltd.
Imagine a world where AI detects breast cancer through a bra. That world is just a “few”months away.
My dad always said read between the lines...tic toc tic...
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
New Investor Information: Take 5 min answers many questions, take 25 & learn more than u care !!!
New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more(DOES NOT include Europe/Canada/Mexico/S Amer.)
In the long run pps is conservative using a low 10% mkt share, as we have NO tested or proven comp.
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
Cyrcadia Inc is the mother Co., Cyrcadia Health & Cyrcadia Asia are affiliated
Cyrcadia Health website is under revision as of recently & most likely will reopen
upon product launch or before... Lifeline Biotechnologies owns approximately 47%
of CH, same CEOs...Lifeline Biotechnologies website has been closed as CH updated
website will replace it...yes it’s been many years etc to get the iTBra to a level of technological
sophistication, but with advanced sensor, AI technology, demand & clinical proff of efficacy (FDA Class11
approval) the product is finally coming to market.
Launch announcement exerts:
Reno, NV , Feb. 28, 2018 (GLOBE NEWSWIRE) --
Lifeline Biotechnologies, Inc, (“The Company”) (OTC PINK: LLBO) Provides Information to the Public and Updates It’s Shareholders.
Jim Holmes, Lifeline’s Cyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs.”
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
by admin | Feb 21, 2018 | News |
“Our priority now is to finalize and implement our marketing plan enabling the ramp up of sales as soon as possible in 2018 upon product delivery.”
“On behalf of the Cyrcadia, Inc. team, we thank you for your support as we bring this life saving technology to market. We will make every effort to ensure timely and profitable delivery of CI’s technology to the “U.S. market”and rest of world outside of the territories covered by CA.”
Sincerely,
Matt Benardis
CEO
Cyrcadia, Inc
Rob Royea Cyrcadia Asia CEO: Jan 2019 launch interview
Oct 31 2018: (I believe part 2 is Jan launch discussion)
https://cyrcadia.asia/2018/10/31/hkibc-all-about-money-features-rob-royea-cyrcadia-asia/#more-676
Reno, NV May 29, 2018, Cyrcadia Health “B” Warrant Acceleration Option
by admin | May 29, 2018 | News
Based on 2018 Go-To-Market plans, investment infusion is paramount in keeping on track and maintaining our accelerated pace. Our stakeholders have been essential in supporting our march to bring the most advanced Breast Health product to market.
“Principals of these companies have been involved with Cyrcadia Health for a number of years and have a deep understanding of our value proposition to bring significant value to our Go-To-Market launch,” says Matt Benardis, CEO.
May 4, 2018, Reno, NV. Expanded Go-To-Market Team
by admin | May 4, 2018 | News
Cyrcadia, Inc. is pleased to announce the addition of Marly Heidkamp, Chief Operating Officer, R.N., MSEd to the executive team to focus on execution of the Go-to- Market plan. Jim Holmes, CFO, say, “We are pleased to have an operations executive join our team who possesses medical product management experience as well. We are confident her leadership will bring added perspective to a product targeted for the female population.” Matt Benardis, CEO, added “We have already seen results from her leadership of the recent kick-off meeting with the comprehensive Go-To- Market team and her engagement of each department regarding oversight, organization and accountability.”
The human element of IoE changing the way breast cancer is detected
TechNovember 03, 2015 08:47
By Vatsun Thirapatarapong
10,540 Viewed
exerts-
Cisco and Cyrcadia Health are involved in the development of an “ iTBra”...
, iTBra will provide thousands of women with early warnings of cancer formation, enabling doctors to implement treatment plans to save lives in time.
Cisco has been following Cyrcadia Health’s efforts closely as their work is a major example of how innovation, made possible by the Internet of Everything, can change and ultimately save lives...
Cisco is chronicling the story of the iTBra by funding a documentary scheduled for release later this year...
More important, is the story of how the connected health industry – poised to be a billion market by 2018 – could change everything we know about medicine.
iTBra is only one example of the Internet of Everything at work in the healthcare industry. In the next three to five years, the number of health-related connected devices will soar. The globally connected health market will grow at an annual growth rate of 33 percent by 2019.
China's AI leader iFLYTEK invests in breast cancer detection wearable Cyrcadia Asia
2018-07-16 09:00:
exerts-
The Pre-A funding enables Cyrcadia to complete product development and launch into Hong Kong and other Asian markets in late 2018...
Commenting on the deal, Tao Xiaodong iFlytech Med Dir.,said: "We are excited to play a leading role in the development and launch of Cyrcadia's technology. iFlytek is already harnessing the power of AI in healthcare, but Cyrcadia's technology,...
As Cyrcadia's user base grows, it has the potential to be the world's largest data base of breast health and breast cancer incidence...
Asia Co-Investors Club
(Past Events)
exert-
Rob Royea, CEO of Cyrcadia Asia, shared his journey with us on 8th October, from the initial idea to the launch of a path-breaking device that has the potential to save millions of lives.
September 21, 2018
Ameing for Asia
exert-
High Demand for Breast Cancer Diagnosis and Treatment Products in Asia
iTBra, through its Hong Kong subsidiary. The company plans a further expansion into China, Indonesia, Malaysia, the Philippines, Singapore and Thailand before the end of the year...
Swiss Association & Swiss Chamber of Commerce
Joint Monthly Luncheon,
Oct8 2018
"Detected"
Guest Speaker: Rob Royea CEO, Cyrcadia Asia, Ltd.
Imagine a world where AI detects breast cancer through a bra. That world is just a “few”months away.
My dad always said read between the lines...tic toc tic...
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
My TD guy says 26 Mil plus shares traded —otc is way out of wack (there also missing trades)!
Yep your right not 41mill, my level 2 was crazy not sour what happened!
Vol 41 mill, ask .003
Up 43% yes sir Big block time, Ground control to Major Tom...
Day traders kickin in...ahhh the good old days
10,000 shares who the hell sells 10,000 shares...one guess, but I can’t say it here...? ( iT ain’t little Jimmy)
Come one Come all
Come Big and Small
Let all the colours of the rainbow fly
Bring the fellas and the girls
And the dreamers of the world
And you can let your own light shine...
Good open strong Bid size, no one wants to sell...be hard for the day guys until Boom
Oops sorry about that...I’m goin to quick here!!!
O/S is not speculation it’s hard data. Speculative subjective growth stock valuation is subjective, I’ve done my analysis & sit quite comfortably on my 1.9 million shares (.05-.07 soon, .22 longer term on current data).This
stock was a day trader 10 yrs ago for me, finally a long term position for speculative growth stock portfolio.
While market cap represents the market perception of a company’s valuation, it still remains the overall market perception and may not necessarily represent the true picture.
Speculative growth investing is highly attractive to many investors because buying stock in emerging companies can provide impressive returns...
Growth investors investigate whether the company has the potential for excelerated revenue streams going forward, I’d say we have an open field of growth coming as we have no competition.
Post #27131–PPS valuation (don’t like it, that’s fare, but if your going to claim too many O/S, back it up)
Tic toc tic...
Open tomorrow should be fun, sleep well LLBO investors!
New Investor Information: Take 5 min answers many questions, take 25 & learn more than u care !!!
New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more(DOES NOT include Europe/Canada/Mexico/S Amer.)
In the long run pps is conservative using a low 10% mkt share, as we have NO tested or proven comp.
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
Cyrcadia Inc is the mother Co., Cyrcadia Health & Cyrcadia Asia are affiliated
Cyrcadia Health website is under revision as of recently & most likely will reopen
upon product launch or before... Lifeline Biotechnologies owns approximately 47%
of CH, same CEOs...Lifeline Biotechnologies website has been closed as CH updated
website will replace it...yes it’s been many years etc to get the iTBra to a level of technological
sophistication, but with advanced sensor, AI technology, demand & clinical proff if efficacy (FDA Class11
approval) the product is finally coming to market.
New Investors: announcement video—the 2-part video what it is,when to market, other product avenues
(Can also be found under Media—Cyrcadiaasia.com)
https://cyrcadia.asia/2018/10/31/hkibc-all-about-money-features-rob-royea-cyrcadia-asia/#more-676
New Investor Information:
New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
Cyrcadia Inc is the mother Co., Cyrcadia Health & Cyrcadia Asia are affiliated
Cyrcadia Health website is under revision as of recently & most likely will reopen
upon product launch or before... Lifeline Biotechnologies owns approximately 47%
of CH, same CEOs...Lifeline Biotechnologies website has been closed as CH updated
website will replace it...yes it’s been many years etc to get the iTBra to a level of technological
sophistication, but with advanced sensor, AI technology, demand & clinical proff if efficacy (FDA Class11
approval) the product is finally coming to market.
Ground Control To Major Tom...8Mil on the Bid Level 2
Up 20%
Ground Control to Major Tom
Ground Control to Major Tom
Take your protein pills
And put your helmet on
Ground Control to Major Tom
Commencing countdown
Engines on
Check ignition
And may God's love (Liftoff) be with you ...Boom
“Ground Zero”——thnx E72
Linkedin: Profile
Kelli McGinnis Royea (wife of Rob Royea Cyrcadia Asia CEO)
Women's Health Liaison at Cyrcadia AsiaHong Kong103
Health, Wellness and Fitness
Summary:
Currently living in Hong Kong, ground zero for launch of the iTBra, a wearable early breast cancer screening device.
Passionate about population healthcare with a mission to transform the industry by increasing breast health awareness, screening accuracy, and accessibility. Empowering women by putting lifesaving technology where it belongs, into their hands.
Experience:?Women's Healthcare Liaison?Cyrcadia Asia, Ltd.?2015 – Present 3 years?Hong Kong??Optometric Technician?Foothill Optometric Group?October 2009 – May 2017 7 years 8 months?Pleasanton, CA
Education:?University of Wisconsin-Milwaukee?Bachelors, Health Services/Allied Health/Health Science
New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
The Run Is On...(game time folks, we’re in the Majors now), what the hell someone had to call it...tic toc tic
Sorry didn’t mean 3600% before announcement news, but definitely going to show activity before launch announcement, blame it on the printer !!!
brogger Good finds. She (Royea) is Also active on Twitter. Did not know she was this active, launch
coming folks, finally the real deal $$$$...Also buylow nice post, I looked at the chart you’re right on and I agree
with a pre announcement run just the nature of the beast every bit 3600% tic toc tic...Boom
Hats off to “ALL” the contributors here...it’s been a long road, but I agree greener pastures r coming...
Lifeline Biotechnologies PPS
PPS Est .22 Cents
LLBO
(It’s a journey so stay with me)
EBITDA PPS valuation for small/midsize CO’s. is 5-7x earnings. EBITDA(Earnings before interest taxes depreciation and amortization)
Let’s Compute PPS using the above commonly used securities formula:
Cyrcadia Health CH
Cyrcadia Asia
CA
~40 Million Mammograms not including other breast screenings per yr USA, not including the rest of the world.
But, (Asia breast cancer screening market size is expected to cross over US $4 Billion by 2022, @ US ~avg cost $100ea this equals 40 million Asian breast screenings annually). iT Bra to begin Asia Dist this January. If CA iTBra gets 10% of that Mkt ((current female population of Asia is 2,550,000,000
BILLION (say what!)
49.6 % of women population is urban, median age is 31—4Mil iTBras no problem)) = 4,000,000mil users x $150= $600Mil revenue ((CA iTBra-12 scans uploaded per yr for a total annual cost of ~$150 info provided by CA)) & avg gross EBITDA profit of 45% (600x.45)=
$270Mil at 5X that profit =(270x 5)= $1.350 Billion Cyrcadia Asia value).
USA value is equivalent given equal market comparison, so (1.35+1.35)=
$2.7 Billion combined CH/CA value using EBITDA standards @ 5x earnings (Not 7x), & most recent Co. data released.
(That’s the big picture, & the one I believe the Mkt will react to given my past experience)
So LLBO PPS:
LLBO owns 47% of CH ...So
CH Val including CA% ownership (per Fin. Info released & some Algebra is
1.35Bil CH +103Mil CA = $1.453Bil total CH value, so LLBO .47 x 1.453=
$683 Mil LLBO value.
Stay with me now
So 683/3.1bil shares O/S =
LLBO stock price of $.22 PPS USA & Asia only.
(No S Amer., Europe, Russia, Australia...)
Total Company & affiliates est value
CH $26 PPS ~27Mil shares O/S
CA $51 PPS ~34Mil sharesO/S
LLBO $.22 ~3.1
Bill shares O/S
Above numbers only include USA & Asia (no Europe, Russia,etc) the world wide market expenditure on breast cancer is ~ One “Trillion” US Dollars $1 Trillion
(Now obviously something as big as breast cancer & the need for alternative solutions, not to mention the —-“only” ——present way to get into the upcoming product launch is “LLBO stock” & don’t take that lightly.
Share price could fluctuate to higher levels on speculative value & it’s my personal opinion they will. I leave it up to the market as to where speculative PPS goes ?
(iTBra has FDA clearance)
(All of the above information was derived by using readily available breast cancer research information. Cyrcadia Inc released public financial info., iTBra target selling prices recently released & info such as CH CA % ownership, CA issued shares to CH, CA owned shares of CH, LLBO CH share holdings, applied mathematics & other info.
As PPS valuation is never an exact science I did my best to use hard data with as little speculation as possible IE: For instance what woman would not want to beat 1:8 odds of getting invasive breast cancer? Think of how many lottery tickets you’d buy with those odds. Thus my speculative 10% of breast screening market for PPS valuation ! (Hell, don’t like 10% use 2% still a hell of a PPS)
Also, Keep in mind the iTBra is not going to reduce the breast screening market
I merely use breast screening & statistics as a fixed point as it’s hard data.
GLTA
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
| Feb 21, 2018 |
——Exert——
“The intent is to launch into both the consumer and Over the Counter (OTC) markets almost simultaneously with the clinical markets. Thus far, indications are favorable for this approach and we will be meeting directly with the FDA in the months to come, declaring our intent. We will report again on the meeting outcomes once definitive. Moreover, CI will pursue a Modified 510(k) through the FDA enabling the rapid expansion of the clinical markets. This does not preclude us from going to market with our existing 510(k), Class II clearance (see the NFJ position above), but will certainly enhance our visibility and buy-in from the medical/clinical community.
On behalf of the Cyrcadia, Inc. team, we thank you for your support as we bring this life saving technology to market. We will make every effort to ensure timely and profitable delivery of CI’s technology to the U.S. market and rest of world outside of the territories covered by CA.
Sincerely,
Matt Benardis
CEO
Cyrcadia Health
“How brands are using AI and VR to boost health care and predict trends”
BY DIANE YOUNES
20 SEP 2018
——-Exerpt——
Lau is keeping a close eye on a specific start-up, which is using AI to link fashion and health care.
For Asian women, our biology and size means that the current standard of mammography is not as accurate as it needs to be.
“What Cyrcadia is doing with AI and breast cancer detection is a game-changer.”
Have a good Thanksgiving &
HO HO HO Merry Christmas, Happy Holidays & Happy Any other Holiday Celebrated by all ...to all !
:>)And to the negatives out there, piles of smiles :)
WOW Well well well, let’s see what Leon Wang: Princeton University Phd researching cancer has to say about the iTBra-
““Skin patches are noninvasive, discrete, and potentially inexpensive enough that I could actually see use by common people on an ordinary basis. Specifically for Cyrcadia and iTBra™, the potential market is huge. There are over 700 million women worldwide between the ages of 20 and 70. In the United States alone, 38 million mammograms are preformed each year. Furthermore, the unacceptably high false positive rate of mammograms leads to an associated cost of over 4 billion dollars in unnecessary treatments annually in the US. If marketed correctly, iTBra™ is not only just a mammogram alternative, it could dominate the entire market
The Bottom Line
Cyrcadia sits on a very mature and proven technology that presents a solution to a “huge” market in which there is no current gold standard. This situation is unique in the startup field and I am very optimistic regarding the future success of iTBra™ and Cyrcadia.””
Tic toc tic...ground control to major Tom ...
PPS .22 ??? Or should I recalculate...let’s say on the upside
Full article link:
https://medium.com/startupreview/the-future-of-cancer-diagnostics-vol-3-e3188fefee41